Top Markets
#1 MowCat MowCat +49.01%
#2 Derive Derive +22.98%
#3 Audiera Audiera +21.36%
#4 Velvet Velvet +19.74%
#5 Biconomy Biconomy +17.74%
#6 Geodnet Geodnet +16.44%
#7 aPriori aPriori +13.80%
#8 Quack AI Quack AI +13.49%
#9 Cross Cross +13.44%
#10 Humanity Humanity +11.22%
Coin of the day
MowCat MowCat
設定
言語
日本
通貨
USD
テーマ
Dogwood Therapeutics, Inc. Dogwood Therapeutics, Inc.

Dogwood Therapeutics, Inc.

DWTX
株式のランク #35719
Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to... Dogwood Therapeutics, Inc. is an emerging biotechnology firm dedicated to creating innovative antiviral treatments. Their primary goal is to address illnesses that stem from atypical immune reactions provoked by viral infections. Its leading therapeutic candidate, IMC-1, is a precise fixed-dose combination of famciclovir and celecoxib, engineered to combat fibromyalgia. Additionally, the company is advancing IMC-2, which blends valacyclovir and celecoxib, aiming to alleviate the array of symptoms linked to long COVID, including persistent fatigue, sleep disturbances, cognitive issues, pain, autonomic dysfunction, and anxiety. Previously operating as Virios Therapeutics, Inc., the organization adopted the name Dogwood Therapeutics, Inc. in October 2024. Established in 2012, the company maintains its main office in Alpharetta, Georgia.
株価
$1.84
最終同期: 2026-08-11
時価総額
$3.51M
変化（1日）
0.46%
変化（1年）
-62.71%
国
US
取引 Dogwood Therapeutics, Inc. (DWTX)

カテゴリー

Healthcare
Dogwood Therapeutics, Inc.（DWTX）の収益
Aug 2026 時点の収益 TTM: 0
Dogwood Therapeutics, Inc. の最新の財務報告によると、現在の収益 (TTM) は 0 です。2026 年には 0 の収益があり、これは 2026 年の 0 と比較して 同等 です。収益とは、企業が商品やサービスの販売によって得る総所得です。利益とは異なり、費用は差し引かれません。
Dogwood Therapeutics, Inc. の収益履歴（2026 ～ 2026）
各年末の収益
年 収益 変化
提供された日付のデータは十分ではありません。
同業他社の収益
企業 収益 収益の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 $10.11B -
BE